An in situ oxidation strategy towards overcoming hERG affinity.
Pryde
David C
DC
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom. david.pryde@pfizer.com
Jones
Rhys
R
Middleton
Donald S
DS
Laverty
Ben J
BJ
Fenwick
David R
DR
Mason
Helen J
HJ
Corless
Martin
M
Smith
Nick N
NN